These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 8535945)
21. Choosing drug therapy for multiple sclerosis. An update. van Oosten BW; Truyen L; Barkhof F; Polman CH Drugs; 1998 Oct; 56(4):555-69. PubMed ID: 9806103 [TBL] [Abstract][Full Text] [Related]
22. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
23. Multiple sclerosis: a review of existing therapy and future prospects. Khan OA J Pak Med Assoc; 1996 Jan; 46(1):20-4. PubMed ID: 8830165 [TBL] [Abstract][Full Text] [Related]
24. Combined immunoglobulin and azathioprine in multiple sclerosis. Kalanie H; Tabatabai SS Eur Neurol; 1998; 39(3):178-81. PubMed ID: 9605396 [TBL] [Abstract][Full Text] [Related]
30. [Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials]. Ozawa K; Saida T Rinsho Shinkeigaku; 1995 Dec; 35(12):1501-3. PubMed ID: 8752444 [TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive treatment of multiple sclerosis. Carter JL; Rodriguez M Mayo Clin Proc; 1989 Jun; 64(6):664-9. PubMed ID: 2473360 [TBL] [Abstract][Full Text] [Related]
32. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Sørensen PS J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763 [TBL] [Abstract][Full Text] [Related]
33. Therapy of multiple sclerosis in children and adolescents. Tenembaum SN Clin Neurol Neurosurg; 2010 Sep; 112(7):633-40. PubMed ID: 20471159 [TBL] [Abstract][Full Text] [Related]
34. The treatment of multiple sclerosis: current and future. Polman CH; Hartung HP Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119 [TBL] [Abstract][Full Text] [Related]
35. [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?]. Schmidt S Nervenarzt; 2010 Oct; 81(10):1231-41. PubMed ID: 20567960 [TBL] [Abstract][Full Text] [Related]
36. [Long-term effects of glatiramer acetate in multiple sclerosis]. Brochet B Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510 [TBL] [Abstract][Full Text] [Related]
37. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Ziemssen T; Neuhaus O; Hohlfeld R Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654 [TBL] [Abstract][Full Text] [Related]
38. Teriflunomide for multiple sclerosis. He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682 [TBL] [Abstract][Full Text] [Related]
39. Glatiramer acetate for multiple sclerosis. La Mantia L; Munari LM; Lovati R Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733 [TBL] [Abstract][Full Text] [Related]
40. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Mahdi-Rogers M; Swan AV; van Doorn PA; Hughes RA Cochrane Database Syst Rev; 2010 Nov; (11):CD003280. PubMed ID: 21069674 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]